Disclosures for "Ableist Language in Goals of Care Discussions in the Neurocritical Care Unit"
-
Ms. Liu has nothing to disclose.
-
Ms. Cerilli has nothing to disclose.
-
Dr. Carhuapoma has nothing to disclose.
-
The institution of Dr. Swenor has received research support from NIH. Dr. Swenor has received personal compensation in the range of $500-$4,999 for serving as a presenter and/or expert advisor with AHRQ, American Chemical Society, Boston Childrens, IVI, Urban Institute, Macy Foundation, NORC.
-
Dr. Muehlschlegel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acasti Pharma Inc.. Dr. Muehlschlegel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acasti Pharma Inc.. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of an immediate family member of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from Johns Hopkins Stimulating and Advancing Anesthesiology & Critical Care Medicine Research (StAAR) Award. The institution of Dr. Muehlschlegel has received research support from Trustees of The Patrick and Catherine Weldon Donaghue Medical Research Foundation. The institution of Dr. Muehlschlegel has received research support from Harkin Family Fund (Johns Hopkins Dept. of Neurology). Dr. Muehlschlegel has received personal compensation in the range of $500-$4,999 for serving as a Speaker and Author with American Academy of Neurology. Dr. Muehlschlegel has a non-compensated relationship as a Member of Board of Directors with Neurocritical Care Society that is relevant to AAN interests or activities.